Clinical Trial Update: Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. [Phase 2]

View source ↗

Summary

Phase 2 trial update for HuMax-CD4 in cutaneous T-cell lymphoma (skin).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• HuMax-CD4

Snippet

Sponsor: Genmab | Conditions: Cutaneous T-Cell Lymphoma | Phase 2 | Status: COMPLETED